文献速递胰腺与胆道疾病消化内镜消化道肿瘤与早癌

恶性肝门部胆道梗阻的最佳支架置入策略:一项大型多中心平行研究

Optimal stent placement strategy for malignant hilar biliary obstruction: a large multicenter parallel study.
PubMed 文献 · Gastrointest Endosc · 2019-12-25

该多中心研究回顾了1239例晚期恶性肝门部胆道梗阻患者,经倾向性评分匹配后比较双侧金属支架、单侧金属支架、双侧塑料支架和单侧塑料支架四种策略。结果显示双侧金属支架在临床成功率、支架通畅期和总生存期方面最优,单侧金属支架次之。

要点

  • 双侧金属支架临床成功率98.9%,显著高于其他三组。
  • 金属支架在各项结局指标上均优于塑料支架。
  • 双侧支架在临床成功、支架通畅和总生存上优于单侧。

核心结论

  • 若技术可行,双金属支架置入是不可手术恶性肝门部胆道梗阻的首选姑息治疗,单侧金属支架为第二选择。

研究设计与样本

  • 多中心回顾性平行研究,纳入4家三级中心的1239例接受内镜支架置入作为主要治疗的晚期恶性肝门部胆道梗阻患者。
  • 经筛选后633例合格患者分为双侧金属支架组、单侧金属支架组、双侧塑料支架组和单侧塑料支架组,并在倾向性评分匹配前后比较结局。
  • 倾向性评分匹配后,双侧金属支架、单侧金属支架、双侧塑料支架和单侧塑料支架组分别匹配87例、97例、91例和81例患者。

主要发现

  • 倾向性评分匹配后,双侧金属支架、单侧金属支架、双侧塑料支架和单侧塑料支架组的临床成功率分别为98.9%、83.5%、71.4%和65.4%(P < .001)。
  • 术后胆管炎发生率分别为8.0%、17.5%、26.4%和29.6%(P = .002)。
  • 中位无症状支架通畅期分别为9.6、6.8、4.6和4.2个月(P < .001)。
  • 平均所需干预次数分别为1.2 ± 0.5、1.7 ± 0.8、2.0 ± 1.4和1.9 ± 1.3(P < .001)。
  • 中位总生存期(95%置信区间)分别为7.1(6.0-8.2)、4.4(3.8-4.9)、4.1(2.9-5.2)和2.7(1.8-3.7)个月(P = .001)。

关键数值与推荐

  • 与塑料支架置入相比,金属支架置入在所有结局参数上均取得更高成功率(P ≤ .001)。
  • 双侧支架置入在临床成功(P = .024)、支架通畅(P = .018)和总生存期(P = .040)方面优于单侧支架置入。

临床怎么用

  • 对于不可手术的恶性肝门部胆道梗阻,若技术可行,优先选择双侧金属支架置入进行姑息治疗。
  • 当双侧金属支架置入不可行时,单侧金属支架置入可作为第二选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: The endoscopic management of malignant hilar biliary obstruction (MHBO) remains extremely challenging without universal consensus. For the first time, we compared 4 major modalities aiming to determine the optimal strategy. METHODS: We reviewed 1239 patients with advanced MHBO who underwent endoscopic stent placement as the primary treatment in 4 tertiary centers. Among them, 633 eligible patients were identified and classified into 4 groups: bilateral metal stent placement (BMS), unilateral metal stent placement (UMS), bilateral plastic stent placement (BPS), and unilateral plastic stent placement (UPS). The outcomes were compared before and after propensity score matching (PSM). RESULTS: After PSM, 87, 97, 91, and 81 patients in the BMS, UMS, BPS, and UPS groups, respectively, were matched. The clinical success rates were 98.9%, 83.5%, 71.4%, and 65.4% in the BMS, UMS, BPS, and UPS groups (P < .001), respectively. The postprocedural cholangitis rates were 8.0%, 17.5%, 26.4%, and 29.6% (P = .002), respectively. The median symptom-free stent patency was 9.6, 6.8, 4.6, and 4.2 months (P < .001), respectively. The mean number of interventions required was 1.2 ± 0.5, 1.7 ± 0.8, 2.0 ± 1.4, and 1.9 ± 1.3 (P < .001), respectively. The median (95% confidence interval) overall survival (OS) was 7.1 (6.0-8.2), 4.4 (3.8-4.9), 4.1 (2.9-5.2), and 2.7 (1.8-3.7) months (P = .001), respectively. Compared with plastic stent placement, metal stent placement achieved higher success in all outcome parameters (P ≤ .001). Bilateral stent placement was superior to unilateral stent placement in terms of clinical success (P = .024), stent patency (P = .018), and OS (P = .040). CONCLUSIONS: If technically possible, dual metal stent placement is a preferred palliation for inoperable MHBO, and unilateral metal stent placement is the second option.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Xia MX, Cai XB, Pan YL, et al. Optimal stent placement strategy for malignant hilar biliary obstruction: a large multicenter parallel study. Gastrointest Endosc. 2019. PMID: 31881205. doi:10.1016/j.gie.2019.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。